Fredun Pharmaceuticals Ltd
Q1 FY27, unaudited
- Revenue
- ₹227.76 Cr
- Profit after tax
- ₹13.13 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 227.76 | +90.75% | 633.33 |
| Other income | 0.49 | +8.91% | 5.80 |
| Total income | 228.25 | +90.44% | 639.12 |
| Employee benefit expense | 7.12 | −6.72% | 32.94 |
| Finance costs | 8.62 | +31.94% | 39.30 |
| Depreciation & amortisation | 3.57 | +151.63% | 8.25 |
| Total expenses | 207.70 | +87.43% | 592.13 |
| Profit before tax | 20.55 | +127.33% | 47.00 |
| Tax expense | 7.42 | +226.19% | 14.38 |
| Profit after tax | 13.13 | +94.10% | 32.62 |
| Total comprehensive income | 13.13 | +94.10% | 32.79 |
| Earnings per share, basic | ₹23.82 | ₹66.81 |
|---|---|---|
| Earnings per share, diluted | ₹22.19 | ₹61.23 |
Earnings call
Q1 FY27Fredun Pharmaceuticals reported Q1 FY27 standalone total income of INR228.25 crores, up 90.44% year-on-year, with EBITDA of INR32.78 crores and net profit of INR13.17 crores. Management attributed part of the growth to booking additional customer orders at older prices ahead of a price increase in the prior quarter. Management also discussed growth plans across its new-age brands, GX division, pet care business including the Wagr platform, working capital, inventory days, and capex for the coming years.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 67 published by the exchange
12 Oct 2026
08 Oct 2026
05 Oct 2026
Filing05 Oct 2026
03 Oct 2026
Filing03 Oct 2026
28 Sept 2026
Insider trading22 Sept 2026
Filing22 Sept 2026
22 Sept 2026
16 Sept 2026
Filing16 Sept 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 12 Oct 2026.